Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. (Q33990433)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833557%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

review article

1 reference

title

Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833557%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833557%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Marianne D Sadar

series ordinal

1

1 reference

30 July 2017

11 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833557%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

published in

World Journal of Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833557%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833557%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833557%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

311-318

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833557%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00345-011-0745-5

10 February 2020

exact match

0 references

cites work

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

A surface on the androgen receptor that allosterically regulates coactivator binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Non-competitive androgen receptor inhibition in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Androgen receptor decoy molecules block the growth of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Intrinsically disordered proteins are potential drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0745-5

Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways

21 January 2018

1 reference

12 December 2020

Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator

1 reference

12 December 2020

Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer

1 reference

12 December 2020

Biological studies on an anti-androgen (SH 714)

1 reference

12 December 2020

Specific recognition of androgens by their nuclear receptor. A structure-function study

1 reference

12 December 2020